Legis Daily

Make Medicine Affordable Act

USA117th CongressHR-7497| House 
| Updated: 4/12/2022
Elissa Slotkin

Elissa Slotkin

Democratic Representative

Michigan

Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee, Education and Workforce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Make Medicine Affordable Act This bill establishes several programs and requirements to address the prices of prescription drugs, including (1) requiring the Centers for Medicare & Medicaid Services to negotiate the prices of certain brand-name drugs and insulin under Medicare, (2) capping annual out-of-pocket spending under the Medicare prescription drug benefit, and (3) limiting cost-sharing for insulin products.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 11, 2022
Introduced in House
Apr 11, 2022
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 12, 2022
Referred to the Subcommittee on Health.
  • April 11, 2022
    Introduced in House


  • April 11, 2022
    Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 12, 2022
    Referred to the Subcommittee on Health.

Health

Related Bills

  • HR 117-6833: Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
  • HR 117-5376: Inflation Reduction Act of 2022
  • HR 117-2815: BIOSIM Act

Make Medicine Affordable Act

USA117th CongressHR-7497| House 
| Updated: 4/12/2022
Make Medicine Affordable Act This bill establishes several programs and requirements to address the prices of prescription drugs, including (1) requiring the Centers for Medicare & Medicaid Services to negotiate the prices of certain brand-name drugs and insulin under Medicare, (2) capping annual out-of-pocket spending under the Medicare prescription drug benefit, and (3) limiting cost-sharing for insulin products.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Apr 11, 2022
Introduced in House
Apr 11, 2022
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Apr 12, 2022
Referred to the Subcommittee on Health.
  • April 11, 2022
    Introduced in House


  • April 11, 2022
    Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.


  • April 12, 2022
    Referred to the Subcommittee on Health.
Elissa Slotkin

Elissa Slotkin

Democratic Representative

Michigan

Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee, Education and Workforce Committee

Health

Related Bills

  • HR 117-6833: Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
  • HR 117-5376: Inflation Reduction Act of 2022
  • HR 117-2815: BIOSIM Act
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted